Zhou Jiahao, Yang Tinghan, Deng Xiangbing, Wang Ziqiang
Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
J Gastrointest Oncol. 2025 Feb 28;16(1):115-127. doi: 10.21037/jgo-24-576. Epub 2025 Jan 6.
Clinical guidelines recommend ≥12 examined lymph nodes (ELNs) for colon cancer staging, but more may be necessary for accuracy. This study utilized nodal staging scores (NSS) to identity the optimal number of ELNs based on tumor location and T stage, and to assess its prognostic impact.
Data from 80,792 patients in the Surveillance, Epidemiology, and End Results (SEER) database (2004-2014) and 2,300 patients from the West China Hospital (WCH) cohort (2008-2014) with stage I-III resected colon cancer were analyzed. Optimal ELNs was estimated using a β-binomial distribution model, stratified by tumor location (left-sided, LS; right-sided, RS) and T stage. The primary outcome was overall survival (OS). The association between sufficient nodal staging and OS in node-negative patients was validated by multivariate Cox models.
The mean number of ELN was 18.75 in the SEER and 14.58 in the WCH database. There were 57.8% and 48.8% patients who had RS colon cancer in the SEER and WCH database. Fewer T3-4 tumors were observed in the SEER cohort compared to the WCH cohort (68.4% 87.2%). Sufficient nodal staging required ≥24 ELNs for T3 tumors, ≥34 nodes for T4 LS tumors, and ≥40 nodes for T4 RS tumors. For T3 lesions, examining 20-29 ELNs were more likely to have node-positive disease [odd ratio (OR) 1.07; 95% confidence interval (CI): 1.01-1.12] compared to patients with 12-15 ELNs. In the T3N0 group, ELN ≥24 was independently associated with better OS in the SEER database [hazard ratio (HR) 0.72; 95% CI: 0.68-0.75], which was validated in the WCH cohort (HR 0.54; 95% CI: 0.38-0.76).
Optimal ELNs for adequate colon cancer staging is related to both T stage and tumor location. We recommend that ≥24 lymph nodes be examined for T3 tumors, ≥34 for LS T4 tumors and ≥40 for RS T4 tumors for sufficient staging.
临床指南推荐对结肠癌进行分期时需检查≥12枚淋巴结(ELN),但为保证准确性可能需要检查更多淋巴结。本研究利用淋巴结分期评分(NSS),根据肿瘤位置和T分期确定ELN的最佳数量,并评估其对预后的影响。
分析了监测、流行病学和最终结果(SEER)数据库(2004 - 2014年)中80792例患者以及华西医院(WCH)队列(2008 - 2014年)中2300例I - III期结肠癌切除患者的数据。使用β - 二项分布模型估计最佳ELN数量,按肿瘤位置(左侧,LS;右侧,RS)和T分期分层。主要结局为总生存期(OS)。通过多变量Cox模型验证淋巴结阴性患者中充分的淋巴结分期与OS之间的关联。
SEER数据库中ELN的平均数量为18.75,WCH数据库中为14.58。SEER和WCH数据库中分别有57.8%和48.8%的患者患有右半结肠癌。与WCH队列相比,SEER队列中观察到的T3 - 4期肿瘤较少(68.4%对87.2%)。T3期肿瘤充分的淋巴结分期需要≥24枚ELN,T4 LS期肿瘤需要≥34枚淋巴结,T4 RS期肿瘤需要≥40枚淋巴结。对于T3期病变,与检查12 - 15枚ELN的患者相比,检查20 - 29枚ELN的患者更有可能出现淋巴结阳性疾病[比值比(OR)1.07;95%置信区间(CI):1.01 - 1.12]。在T3N0组中,SEER数据库中ELN≥24与更好的OS独立相关[风险比(HR)0.72;95% CI:0.68 - 0.75],这在WCH队列中得到验证(HR 0.54;95% CI:0.38 - 0.76)。
结肠癌充分分期的最佳ELN数量与T分期和肿瘤位置均相关。我们建议,为了充分分期,T3期肿瘤应检查≥24枚淋巴结,LS T4期肿瘤应检查≥34枚,RS T4期肿瘤应检查≥40枚。